

21st October, 2025

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub: Disclosure under Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further, to the Media Release titled "Torrent Pharma to acquire controlling stake in J. B. Chemicals & Pharmaceuticals from KKR" dated 29th June 2025 and Stock exchange intimation dated 3rd July, 2025 and 23rd September, 2025, this is to inform you that the Competition Commission of India ("CCI") has granted its approval for the transaction on 21st October, 2025, subject to the parties complying with voluntary modifications to be outlined in CCI's final order.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED